depletion  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Name:
    SARS CoV 2 2019 nCoV Spike RBD His Recombinant Protein COVID 19 Spike RBD Research
    Description:
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike Protein RBD YP 009724390 1 Arg319 Phe541 was expressed with a polyhistidine tag at the C terminus
    Catalog Number:
    40592-V08B
    Price:
    None
    Category:
    recombinant protein
    Product Aliases:
    coronavirus spike Protein 2019-nCoV, cov spike Protein 2019-nCoV, ncov RBD Protein 2019-nCoV, ncov s1 Protein 2019-nCoV, ncov s2 Protein 2019-nCoV, ncov spike Protein 2019-nCoV, NCP-CoV RBD Protein 2019-nCoV, NCP-CoV s1 Protein 2019-nCoV, NCP-CoV s2 Protein 2019-nCoV, NCP-CoV Spike Protein 2019-nCoV, novel coronavirus RBD Protein 2019-nCoV, novel coronavirus s1 Protein 2019-nCoV, novel coronavirus s2 Protein 2019-nCoV, novel coronavirus spike Protein 2019-nCoV, RBD Protein 2019-nCoV, S1 Protein 2019-nCoV, S2 Protein 2019-nCoV, Spike RBD Protein 2019-nCoV
    Host:
    Baculovirus-Insect Cells
    Buy from Supplier


    Structured Review

    Sino Biological depletion
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike Protein RBD YP 009724390 1 Arg319 Phe541 was expressed with a polyhistidine tag at the C terminus
    https://www.bioz.com/result/depletion/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    depletion - by Bioz Stars, 2021-04
    94/100 stars

    Images

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
    Article Snippet: .. Enzyme-linked immunosorbent assay As previously described, 50 ng of SARS-CoV-2 S1 protein (Sino Biological, 40591-V08H) or SARS-CoV-2 RBD protein (Sino Biological, 40592-V08B) or SARS-CoV-2 S2 protein (Sino Biological, 40590-V08B) in 100 μl phosphate-buffered saline (PBS) per well was coated on ELISA plates (Costar, 42592) overnight at 4 °C. .. The ELISA plates were blocked for 1 h with 100 μl blocking buffer (5% fetal bovine serum (FBS) and 0.1% Tween 20 in PBS) and then incubated with diluted patient or healthy control sera in 100 μl blocking buffer for 1 h. After washing with PBST buffer (0.1% Tween 20 in PBS), the ELISA plates were incubated with anti-human IgG horseradish peroxidase (HRP) antibody (Bioss Biotech, 0297D) for 45 min, followed by PBST washing and addition of 3,3′,5,5′-tetramethylbenzidine (TMB) buffer (Beyotime, P0209).

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
    Article Snippet: No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. strictly(RBD(dependent(and(deletion(of(RBD_specific(antibodies( led( to( the( failure( in( neutralization(in(S1_specific(sera. (These(results(highlighted(the(importance(of(S1_RBD( itself,(but(not(other(parts(of(S1(protein,(in(inducing(competent(NAbs. ( ( ( In(conclusion,(we(have(demonstrated(the(positive(correlation(between(the(magnitude( of(NAb(responses(and(disease(severity(in(patients(recovered(from(COVID_19. (We(have( also( found( that( disease( severity( also( influences( the( neutralization( heterogeneity( of( SARS_CoV2_specific(antibodies. (Our(results(highlight(the(needs(to(include(mild_illness( and(asymptomatic(patients(for( future(vaccination,(and(also(suggest( the(collection(of( plasma(from(COVID_19(recovered(patients(should(be(restricted(to(those(with(moderate( to( severe( symptoms( for( passive( antibody( therapy. (Our( data( also( provide( important( rationale( for( exclusively( using( SARS_CoV_2( RBD( as( S1_immunogen( in( COVID_19( vaccine(regime. ( . .. MaterialsHuman(The(59(COVID_19( recovered(patients(enrolled( in( the(study(were( provided(written(informed(consent(and(from(different(sources. (The(sera(of(the(severe,( moderate(and(mild(patients(were(obtained(from(Guangzhou(Eighth(People’s(Hospital. ( The(sera(of(the(asymptomatic(patients(were(obtained(from(Chongqing(Public(Health( Medical(Center. (Healthy(control(subjects(were(4(adult(participants( in( the(study. (The( study(received(IRB(approvals(at(Guangzhou(Eighth(People’s(Hospital((KE202001134)( and(Chongqing(Public(Health(Medical(Center((2020_023_01_KY). ( ELISA. (As(previously(described15,(50(ng(of(SARS_CoV_2(S1(protein((Sino(Biological,( 40591_V08H)(or(SARS_CoV_2(RBD(protein((Sino(Biological,(40592_V08B)(or(SARS_ CoV_2(S2(protein((Sino(Biological,(40590_V08B)(in(100(μl(PBS(per(well(was(coated(on( ELISA(plates((Costar,(42592)(overnight(at(4oC. (The(ELISA(plates(were(blocked(for(1( hour( with( 100( μl( blocking( buffer( (5%( FBS( and( 0.1%( Tween( 20( in( PBS)( and( then( incubated(with(diluted(patient(or(healthy(control(sera(in(100(μl(blocking(buffer(for(1(hour. ( All rights reserved. ..

    Multiplex Assay:

    Article Title: SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence.
    Article Snippet: Assay ProcedureThe steps in assay validation were similar to recently developed bead-based multiplex immunoassays for CMV, EBV, and RSV, with minor modifications as described below [16, 17]. .. For the multiplex bead-based immune assay the following antigens obtained from Sino Biological were used: SARS-CoV-2 monomeric spike S1 (40591-V08H), RBD (40592-V08B), and nucleoprotein (N) (40588-V08B). ..

    Article Title: SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence
    Article Snippet: Assay Procedure The steps in assay validation were similar to recently developed bead-based multiplex immunoassays for CMV, EBV, and RSV, with minor modifications as described below [ , ]. .. For the multiplex bead-based immune assay the following antigens obtained from Sino Biological were used: SARS-CoV-2 monomeric spike S1 (40591-V08H), RBD (40592-V08B), and nucleoprotein (N) (40588-V08B). ..

    Recombinant:

    Article Title: Synthesis of polystyrene-based fluorescent quantum dots nanolabel and its performance in H5N1 virus and SARS-CoV-2 antibody sensing
    Article Snippet: Fluoro-max fluorescent beads with europium chelate was provided from Thermo Fisher Scientific Inc. COOH-coated polystyrene (PS) microbeads (0.2 and 4 μm) were obtained from Huge Biotechnology Co., Ltd (China). .. SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein were obtained from Sino Biological (Beijing). .. Influenza A virus H5N1 HA (Hemagglutinin) antibody were purchased from Gene Tex.

    Incubation:

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
    Article Snippet: No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. after(the(mixture(incubation,(the(luciferase(activity(of(SARS_CoV_2(typed(pseudovirus_ infected(ACE2/293T(cells(were(measured(by(a(luciferase(reporter(assay(kit((Promega,( E1910). ( SARS0CoV02(sera(were(diluted( in(DMEM((40( fold_dilution)( and( mixed( with( an( equal( volume( of( 80_100( PFU( SARS_CoV_2( (EPI_ISL_444969)(for(1(h(at(37°C. (Serum_virus(mixture(were(then(added(to(the(Vero( E6(cell(monolayers(in(48_well(plates(and(incubated(at(37°C(in(5%(CO2(for(1(h.(After( removing(the(inocula,(plates(were(overlaid(with(culture(medium(and(cultured(at(37°C( for(48(h.(Subsequently,(viral(RNA(from(the(cultural(supernatants(was(extracted(and(the( viral(RNA(copies(were(determined(by(quantitative(PCR(according(to(the(viral(detection( kit’s(protocol((DAAN(Gene(Co.,(Ltd.(of(Sun(Yat_Sen(University). (All(experiments(related( to( authentic( viruses( were( performed( in( the( certified( BSL_3( facility( of( Sun( Yat_sen( University.(The(SARS_CoV_2(viral(RNA(fold(reduction(=(2(CT(value(of(sample(_(CT(value(of(mock). .. Depletion(Firstly,(SARS_CoV_2(S1( protein((Sino(Biological,(40591_V08H)(or(SARS_CoV_2(RBD(protein((Sino(Biological,( 40592_V08B)(or(SARS_CoV_2(S2(protein(was(conjugated(with(biotin(by(following(the( manufacture’s( protocol( (Thermo(Fisher(Scientific,(A39257). (Then,( biotin_conjugated( proteins(were(incubated(with(BeaverBeads(Mag(Streptavidin(Matrix((Beaver,(22305)( at(4oC(for(1.5(hours. (After(washing(with(PBS,(the(SARS_CoV_2(S(protein(coupled(beads( were( next( incubated( with( diluted( patient( sera( at( 4oC( for( 1.5( hours. ( Then,( the( supernatants(were(harvested(and(quality(controlled(by(ELISA(assays(for(SARS_CoV_ 2(S(proteins. ( Statistics. (The(SARS_CoV_2(antibody(titers(or(virus(neutralizing(function(of(the(sera( belonging(to(patients(with(different(severity(were(compared(with(the(one_way(ANOVA( test( (Tukey’s( multiple( comparisons( test). ( The( cutoff( value( in( each( pseudovirus( neutralizing(function(assay(was(determined(by(the(ROC(curve(analysis(and(was(of(the( All rights reserved. .. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. highest(likelihood(ratio. (Correlations(between(different(SARS_CoV_2(antibody(titers(or( between(SARS_CoV_2(antibody(titers(and(pseudovirus(titers(or(between(SARS_CoV_2( antibody(titers(and(SARS_CoV_2(virus(titers(were(analyzed(using(Pearson’s(correlation( coefficient. (P( values( less( than( 0.05(were( defied( as( statistically( significant. ( Prism( 6( software(was(used(for(statistical(analysis.

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
    Article Snippet: No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. strictly(RBD(dependent(and(deletion(of(RBD_specific(antibodies( led( to( the( failure( in( neutralization(in(S1_specific(sera. (These(results(highlighted(the(importance(of(S1_RBD( itself,(but(not(other(parts(of(S1(protein,(in(inducing(competent(NAbs. ( ( ( In(conclusion,(we(have(demonstrated(the(positive(correlation(between(the(magnitude( of(NAb(responses(and(disease(severity(in(patients(recovered(from(COVID_19. (We(have( also( found( that( disease( severity( also( influences( the( neutralization( heterogeneity( of( SARS_CoV2_specific(antibodies. (Our(results(highlight(the(needs(to(include(mild_illness( and(asymptomatic(patients(for( future(vaccination,(and(also(suggest( the(collection(of( plasma(from(COVID_19(recovered(patients(should(be(restricted(to(those(with(moderate( to( severe( symptoms( for( passive( antibody( therapy. (Our( data( also( provide( important( rationale( for( exclusively( using( SARS_CoV_2( RBD( as( S1_immunogen( in( COVID_19( vaccine(regime. ( . .. MaterialsHuman(The(59(COVID_19( recovered(patients(enrolled( in( the(study(were( provided(written(informed(consent(and(from(different(sources. (The(sera(of(the(severe,( moderate(and(mild(patients(were(obtained(from(Guangzhou(Eighth(People’s(Hospital. ( The(sera(of(the(asymptomatic(patients(were(obtained(from(Chongqing(Public(Health( Medical(Center. (Healthy(control(subjects(were(4(adult(participants( in( the(study. (The( study(received(IRB(approvals(at(Guangzhou(Eighth(People’s(Hospital((KE202001134)( and(Chongqing(Public(Health(Medical(Center((2020_023_01_KY). ( ELISA. (As(previously(described15,(50(ng(of(SARS_CoV_2(S1(protein((Sino(Biological,( 40591_V08H)(or(SARS_CoV_2(RBD(protein((Sino(Biological,(40592_V08B)(or(SARS_ CoV_2(S2(protein((Sino(Biological,(40590_V08B)(in(100(μl(PBS(per(well(was(coated(on( ELISA(plates((Costar,(42592)(overnight(at(4oC. (The(ELISA(plates(were(blocked(for(1( hour( with( 100( μl( blocking( buffer( (5%( FBS( and( 0.1%( Tween( 20( in( PBS)( and( then( incubated(with(diluted(patient(or(healthy(control(sera(in(100(μl(blocking(buffer(for(1(hour. ( All rights reserved. ..

    Blocking Assay:

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
    Article Snippet: No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. strictly(RBD(dependent(and(deletion(of(RBD_specific(antibodies( led( to( the( failure( in( neutralization(in(S1_specific(sera. (These(results(highlighted(the(importance(of(S1_RBD( itself,(but(not(other(parts(of(S1(protein,(in(inducing(competent(NAbs. ( ( ( In(conclusion,(we(have(demonstrated(the(positive(correlation(between(the(magnitude( of(NAb(responses(and(disease(severity(in(patients(recovered(from(COVID_19. (We(have( also( found( that( disease( severity( also( influences( the( neutralization( heterogeneity( of( SARS_CoV2_specific(antibodies. (Our(results(highlight(the(needs(to(include(mild_illness( and(asymptomatic(patients(for( future(vaccination,(and(also(suggest( the(collection(of( plasma(from(COVID_19(recovered(patients(should(be(restricted(to(those(with(moderate( to( severe( symptoms( for( passive( antibody( therapy. (Our( data( also( provide( important( rationale( for( exclusively( using( SARS_CoV_2( RBD( as( S1_immunogen( in( COVID_19( vaccine(regime. ( . .. MaterialsHuman(The(59(COVID_19( recovered(patients(enrolled( in( the(study(were( provided(written(informed(consent(and(from(different(sources. (The(sera(of(the(severe,( moderate(and(mild(patients(were(obtained(from(Guangzhou(Eighth(People’s(Hospital. ( The(sera(of(the(asymptomatic(patients(were(obtained(from(Chongqing(Public(Health( Medical(Center. (Healthy(control(subjects(were(4(adult(participants( in( the(study. (The( study(received(IRB(approvals(at(Guangzhou(Eighth(People’s(Hospital((KE202001134)( and(Chongqing(Public(Health(Medical(Center((2020_023_01_KY). ( ELISA. (As(previously(described15,(50(ng(of(SARS_CoV_2(S1(protein((Sino(Biological,( 40591_V08H)(or(SARS_CoV_2(RBD(protein((Sino(Biological,(40592_V08B)(or(SARS_ CoV_2(S2(protein((Sino(Biological,(40590_V08B)(in(100(μl(PBS(per(well(was(coated(on( ELISA(plates((Costar,(42592)(overnight(at(4oC. (The(ELISA(plates(were(blocked(for(1( hour( with( 100( μl( blocking( buffer( (5%( FBS( and( 0.1%( Tween( 20( in( PBS)( and( then( incubated(with(diluted(patient(or(healthy(control(sera(in(100(μl(blocking(buffer(for(1(hour. ( All rights reserved. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Sino Biological sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research
    Detection of <t>SARS-CoV-2</t> antibodies in human saliva. (a) A confocal fluorescence image of IgG signals in the saliva of 4 recovered COVID-19 patients (denoted as P1-P4) and 11 healthy controls (denoted as P5-P15) and a 10 4 times diluted serum of a PCR-confirmed COVID-19 patient as a reference (denoted as ‘Ref’). Saliva was collected by a simple spitting method as shown in the schematic. (b) Median fluorescence intensity (MFI) signals of anti-S1 and anti-RBD IgG measured in the saliva samples and PCR-positive COVID-19 serum reference with background signals subtracted. The error bars indicate one standard deviation away from the mean.
    Sars Cov 2 2019 Ncov Spike Rbd His Recombinant Protein Covid 19 Spike Rbd Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research - by Bioz Stars, 2021-04
    97/100 stars
      Buy from Supplier

    Image Search Results


    Detection of SARS-CoV-2 antibodies in human saliva. (a) A confocal fluorescence image of IgG signals in the saliva of 4 recovered COVID-19 patients (denoted as P1-P4) and 11 healthy controls (denoted as P5-P15) and a 10 4 times diluted serum of a PCR-confirmed COVID-19 patient as a reference (denoted as ‘Ref’). Saliva was collected by a simple spitting method as shown in the schematic. (b) Median fluorescence intensity (MFI) signals of anti-S1 and anti-RBD IgG measured in the saliva samples and PCR-positive COVID-19 serum reference with background signals subtracted. The error bars indicate one standard deviation away from the mean.

    Journal: bioRxiv

    Article Title: High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform

    doi: 10.1101/2020.06.16.155580

    Figure Lengend Snippet: Detection of SARS-CoV-2 antibodies in human saliva. (a) A confocal fluorescence image of IgG signals in the saliva of 4 recovered COVID-19 patients (denoted as P1-P4) and 11 healthy controls (denoted as P5-P15) and a 10 4 times diluted serum of a PCR-confirmed COVID-19 patient as a reference (denoted as ‘Ref’). Saliva was collected by a simple spitting method as shown in the schematic. (b) Median fluorescence intensity (MFI) signals of anti-S1 and anti-RBD IgG measured in the saliva samples and PCR-positive COVID-19 serum reference with background signals subtracted. The error bars indicate one standard deviation away from the mean.

    Article Snippet: Multiplexed SARS-CoV-2 microarray printing on pGOLD slidesEach pGOLD slide (Nirmidas Biotech Inc.) was printed with two SARS-CoV-2 antigens, namely the spike protein S1 subunit (S1) and S1 containing the receptor binding domain (RBD), using a GeSiM Nano-Plotter 2.1 at the following concentrations: 60 μg/mL for S1 (40591-V08H, Sino Biological Inc.) and 25 μg/mL for RBD (40592-V08H, Sino Biological Inc.).

    Techniques: Fluorescence, Polymerase Chain Reaction, Standard Deviation

    Antibody avidity against SARS-CoV-2 antigens. (a) Avidity of anti-S1 IgG and anti-RBD IgG measured in IgG-positive, PCR-confirmed COVID-19 patient sera collected 6-45 days post symptom onset. The serum of PAMF-065 showed unusually high avidity for anti-S1 IgG while being negative for anti-RBD IgG. (b) Upper panel: Fluorescence images of IgG-only channel showing PAMF-065 serum sample with high anti-S1 IgG level with and without urea treatment, hence high avidity. It showed negligible anti-RBD IgG. Lower panel: Fluorescence images showing another patient serum tested, PAMF-011, with much reduced anti-S1 IgG level after urea treatment, indicating low avidity. Low avidity was observed for all samples except PAMF-065. (c) Anti-S1 IgG median fluorescence intensity (MFI) signals of the PAMF-065 sample with and without urea treatment. The error bars indicate one standard deviation away from the mean.

    Journal: bioRxiv

    Article Title: High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform

    doi: 10.1101/2020.06.16.155580

    Figure Lengend Snippet: Antibody avidity against SARS-CoV-2 antigens. (a) Avidity of anti-S1 IgG and anti-RBD IgG measured in IgG-positive, PCR-confirmed COVID-19 patient sera collected 6-45 days post symptom onset. The serum of PAMF-065 showed unusually high avidity for anti-S1 IgG while being negative for anti-RBD IgG. (b) Upper panel: Fluorescence images of IgG-only channel showing PAMF-065 serum sample with high anti-S1 IgG level with and without urea treatment, hence high avidity. It showed negligible anti-RBD IgG. Lower panel: Fluorescence images showing another patient serum tested, PAMF-011, with much reduced anti-S1 IgG level after urea treatment, indicating low avidity. Low avidity was observed for all samples except PAMF-065. (c) Anti-S1 IgG median fluorescence intensity (MFI) signals of the PAMF-065 sample with and without urea treatment. The error bars indicate one standard deviation away from the mean.

    Article Snippet: Multiplexed SARS-CoV-2 microarray printing on pGOLD slidesEach pGOLD slide (Nirmidas Biotech Inc.) was printed with two SARS-CoV-2 antigens, namely the spike protein S1 subunit (S1) and S1 containing the receptor binding domain (RBD), using a GeSiM Nano-Plotter 2.1 at the following concentrations: 60 μg/mL for S1 (40591-V08H, Sino Biological Inc.) and 25 μg/mL for RBD (40592-V08H, Sino Biological Inc.).

    Techniques: Polymerase Chain Reaction, Fluorescence, Standard Deviation

    Correlation of antibodies against two SARS-CoV-2 antigens. (a) Correlation plot of anti-S1 IgG level (y-axis) and anti-RBD IgG level (x-axis) measured in PCR-confirmed COVID-19 patient sera. The dashed line was drawn to have a slope of 1. The upper left inset shows the scanned image of the IgG-only channel in a patient serum labeled as PAMF-065, which displayed high signal on the S1 antigen but not on the RBD antigen. The lower right inset shows the scanned image of IgG levels of a sample labeled as PAMF-011, displaying about equal IgG signals against S1 and RBD. (b) Correlation plot of anti-S1 IgM level (y-axis) and anti-RBD IgM level (x-axis) measured in COVID-19 patient sera. The dashed line was drawn to have a slope of 1.

    Journal: bioRxiv

    Article Title: High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform

    doi: 10.1101/2020.06.16.155580

    Figure Lengend Snippet: Correlation of antibodies against two SARS-CoV-2 antigens. (a) Correlation plot of anti-S1 IgG level (y-axis) and anti-RBD IgG level (x-axis) measured in PCR-confirmed COVID-19 patient sera. The dashed line was drawn to have a slope of 1. The upper left inset shows the scanned image of the IgG-only channel in a patient serum labeled as PAMF-065, which displayed high signal on the S1 antigen but not on the RBD antigen. The lower right inset shows the scanned image of IgG levels of a sample labeled as PAMF-011, displaying about equal IgG signals against S1 and RBD. (b) Correlation plot of anti-S1 IgM level (y-axis) and anti-RBD IgM level (x-axis) measured in COVID-19 patient sera. The dashed line was drawn to have a slope of 1.

    Article Snippet: Multiplexed SARS-CoV-2 microarray printing on pGOLD slidesEach pGOLD slide (Nirmidas Biotech Inc.) was printed with two SARS-CoV-2 antigens, namely the spike protein S1 subunit (S1) and S1 containing the receptor binding domain (RBD), using a GeSiM Nano-Plotter 2.1 at the following concentrations: 60 μg/mL for S1 (40591-V08H, Sino Biological Inc.) and 25 μg/mL for RBD (40592-V08H, Sino Biological Inc.).

    Techniques: Polymerase Chain Reaction, Labeling

    A nano-plasmonic platform for SARS-CoV-2 antibody testing. (a) An overlay of confocal fluorescence scanned images of IgG (green) and IgM (red) channels acquired after testing 16 serum samples in 16 isolated wells (square-shaped regions). Yellowish-green colored spots correspond to the presence of both IgG and IgM in the sample. The lower right schematic drawing shows the printing layout of S1 (in green) and RBD (in blue) antigens and human IgG control spots (in white) in each well. The BSA-biotin spots (in red) are always labeled by a streptavidin dye in the IgM fluorescence channel to serve as an intrawell signal normalizer. (b) Box plots of IgG levels detected in PCR-negative COVID-19 or presumptive negative (‘Healthy’) and PCR-positive (‘PCR+’) COVID-19 samples with the cutoff indicated as a dashed red line. (c) The same as (b) except for IgM. (d) ROC curve for pGOLD SARS-CoV-2 IgG/IgM assay based on 384 negative and 62 PCR-positive COVID-19 serum, which was used to establish IgG and IgM cutoffs. (e) ROC curve for pGOLD SARS-CoV-2 IgG/IgM assay based on 384 negative and PCR-positive COVID-19 serum samples collected 15-45 days post symptom onset.

    Journal: bioRxiv

    Article Title: High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform

    doi: 10.1101/2020.06.16.155580

    Figure Lengend Snippet: A nano-plasmonic platform for SARS-CoV-2 antibody testing. (a) An overlay of confocal fluorescence scanned images of IgG (green) and IgM (red) channels acquired after testing 16 serum samples in 16 isolated wells (square-shaped regions). Yellowish-green colored spots correspond to the presence of both IgG and IgM in the sample. The lower right schematic drawing shows the printing layout of S1 (in green) and RBD (in blue) antigens and human IgG control spots (in white) in each well. The BSA-biotin spots (in red) are always labeled by a streptavidin dye in the IgM fluorescence channel to serve as an intrawell signal normalizer. (b) Box plots of IgG levels detected in PCR-negative COVID-19 or presumptive negative (‘Healthy’) and PCR-positive (‘PCR+’) COVID-19 samples with the cutoff indicated as a dashed red line. (c) The same as (b) except for IgM. (d) ROC curve for pGOLD SARS-CoV-2 IgG/IgM assay based on 384 negative and 62 PCR-positive COVID-19 serum, which was used to establish IgG and IgM cutoffs. (e) ROC curve for pGOLD SARS-CoV-2 IgG/IgM assay based on 384 negative and PCR-positive COVID-19 serum samples collected 15-45 days post symptom onset.

    Article Snippet: Multiplexed SARS-CoV-2 microarray printing on pGOLD slidesEach pGOLD slide (Nirmidas Biotech Inc.) was printed with two SARS-CoV-2 antigens, namely the spike protein S1 subunit (S1) and S1 containing the receptor binding domain (RBD), using a GeSiM Nano-Plotter 2.1 at the following concentrations: 60 μg/mL for S1 (40591-V08H, Sino Biological Inc.) and 25 μg/mL for RBD (40592-V08H, Sino Biological Inc.).

    Techniques: Fluorescence, Isolation, Labeling, Polymerase Chain Reaction

    Highly sensitive and specific SARS-CoV-2 antibody test. (a) Percentages of samples with IgG/IgM antibody status combinations according to days from symptom onset to sample collection date in a range from 0-7, 8-14, and 15-45 days. (b) Box plots of IgG levels detected in four groups of serum samples indicated on the x-axis with the cutoff displayed as a dashed red line. ‘PCR+’ denotes serum samples from patients who tested positive by PCR for COVID-19 and ‘PCR-’ denotes those who tested negative. ‘Pre-pand.’ corresponds to pre-pandemic collected samples. ‘Cross R.’ corresponds to samples from patients with other diseases for cross-reactivity evaluation. (c) The same as (b) except for IgM.

    Journal: bioRxiv

    Article Title: High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform

    doi: 10.1101/2020.06.16.155580

    Figure Lengend Snippet: Highly sensitive and specific SARS-CoV-2 antibody test. (a) Percentages of samples with IgG/IgM antibody status combinations according to days from symptom onset to sample collection date in a range from 0-7, 8-14, and 15-45 days. (b) Box plots of IgG levels detected in four groups of serum samples indicated on the x-axis with the cutoff displayed as a dashed red line. ‘PCR+’ denotes serum samples from patients who tested positive by PCR for COVID-19 and ‘PCR-’ denotes those who tested negative. ‘Pre-pand.’ corresponds to pre-pandemic collected samples. ‘Cross R.’ corresponds to samples from patients with other diseases for cross-reactivity evaluation. (c) The same as (b) except for IgM.

    Article Snippet: Multiplexed SARS-CoV-2 microarray printing on pGOLD slidesEach pGOLD slide (Nirmidas Biotech Inc.) was printed with two SARS-CoV-2 antigens, namely the spike protein S1 subunit (S1) and S1 containing the receptor binding domain (RBD), using a GeSiM Nano-Plotter 2.1 at the following concentrations: 60 μg/mL for S1 (40591-V08H, Sino Biological Inc.) and 25 μg/mL for RBD (40592-V08H, Sino Biological Inc.).

    Techniques: Polymerase Chain Reaction

    SARS-CoV-2 vaccine-elicited functional antibody responses in infant rhesus macaques. (A): The ACE2 blocking assay was performed at 1:10 plasma dilution and data are reported as %ACE2 blocking. (B-C) : Neutralization capacity was measured using a pseudovirus assay (B) and whole virus assay (C) ; results are expressed as reciprocal 80% inhibitory dilution (ID 80 ). Different symbols represent individual animals ( Table S1 ).

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: SARS-CoV-2 vaccine-elicited functional antibody responses in infant rhesus macaques. (A): The ACE2 blocking assay was performed at 1:10 plasma dilution and data are reported as %ACE2 blocking. (B-C) : Neutralization capacity was measured using a pseudovirus assay (B) and whole virus assay (C) ; results are expressed as reciprocal 80% inhibitory dilution (ID 80 ). Different symbols represent individual animals ( Table S1 ).

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques: Functional Assay, Blocking Assay, Neutralization

    Spike-specific T cell responses in LN following SARS-CoV-2 vaccination. Intracellular cytokine staining as in Figure 5 in lymph node biopsy samples at week 6 to measure Spike-specific T cell responses. Panels A and B show mRNA-LNP and Protein+3M-052+SE CD4 + T-cell responses, respectively. Panels C and D represent CD8 + T cell cytokine responses from mRNA-LNP and Protein+3M-052+SE animals, respectively. Symbols and the legend mirror those from Figure 6 (see also Table S1 ). Dotted lines represent 2 standard deviations from SARS-CoV-2 naïve LN samples.

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: Spike-specific T cell responses in LN following SARS-CoV-2 vaccination. Intracellular cytokine staining as in Figure 5 in lymph node biopsy samples at week 6 to measure Spike-specific T cell responses. Panels A and B show mRNA-LNP and Protein+3M-052+SE CD4 + T-cell responses, respectively. Panels C and D represent CD8 + T cell cytokine responses from mRNA-LNP and Protein+3M-052+SE animals, respectively. Symbols and the legend mirror those from Figure 6 (see also Table S1 ). Dotted lines represent 2 standard deviations from SARS-CoV-2 naïve LN samples.

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques: Staining

    Spike-specific CD8 + T cell responses in SARS-CoV-2 immunized infant macaques. Intracellular cytokine staining was performed as described in Figure 5 at weeks 0, 6, 4, 8, and 14 to assess CD8 + T-cell responses. Panels A, B, C and D show responses detected in PBMC from the mRNA-LNP group at weeks 4, 6, 8, and 14, respectively. Panels E, F, G and H show responses in Protein+3M-052+SE vaccinees at weeks 4, 6, 8 and 14, respectively. The legend and symbols used mirror those from Figure 6 (see also Table S1 ). Dotted lines represent the cut-off for cytokine-positive responses, determined as 2 standard deviations above median values of SARS-CoV-2 naïve animals.

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: Spike-specific CD8 + T cell responses in SARS-CoV-2 immunized infant macaques. Intracellular cytokine staining was performed as described in Figure 5 at weeks 0, 6, 4, 8, and 14 to assess CD8 + T-cell responses. Panels A, B, C and D show responses detected in PBMC from the mRNA-LNP group at weeks 4, 6, 8, and 14, respectively. Panels E, F, G and H show responses in Protein+3M-052+SE vaccinees at weeks 4, 6, 8 and 14, respectively. The legend and symbols used mirror those from Figure 6 (see also Table S1 ). Dotted lines represent the cut-off for cytokine-positive responses, determined as 2 standard deviations above median values of SARS-CoV-2 naïve animals.

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques: Staining

    Weight gain of SARS-CoV-2 immunized infant rhesus macaques. Longitudinal weight data for all female (top) and male (bottom) animals from this study with their respective symbol shapes and colors ( Table S1 ) overlaid with historical weight data from age and sex-matched infant rhesus monkeys housed outdoors at the CNPRC, Davis California (open black circles-female; filled gray circles-male).

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: Weight gain of SARS-CoV-2 immunized infant rhesus macaques. Longitudinal weight data for all female (top) and male (bottom) animals from this study with their respective symbol shapes and colors ( Table S1 ) overlaid with historical weight data from age and sex-matched infant rhesus monkeys housed outdoors at the CNPRC, Davis California (open black circles-female; filled gray circles-male).

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques:

    Polyfunctional CD4 + T cells in SARS-CoV-2 immunized rhesus macaques at week 14. Panels A and B show the frequencies of CD4 + T cells that co-produced IL-17 and IFN-γ in response to stimulation with spike protein overlapping peptides in animals of the mRNA-LNP or Protein-3M-052-SE vaccine group, respectively. Individual symbols represent individual animals in each group ( Table S1 ).

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: Polyfunctional CD4 + T cells in SARS-CoV-2 immunized rhesus macaques at week 14. Panels A and B show the frequencies of CD4 + T cells that co-produced IL-17 and IFN-γ in response to stimulation with spike protein overlapping peptides in animals of the mRNA-LNP or Protein-3M-052-SE vaccine group, respectively. Individual symbols represent individual animals in each group ( Table S1 ).

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques: Produced

    Characterization of Spike-specific B cell responses two weeks post boost. CD20 + CD27 + memory B cells that co-stained with fluorochrome-conjugated SARS-CoV-2 spike protein in mRNA-LNP (red) or Protein+3M-052-SE (blue) vaccinees in blood ( A - B ) or LN ( C - D ). Frequencies are expressed as percent of total memory B cells. The gating strategy is provided in Supplementary Figure S8. ( E–F) portray antibody secreting cell (ASC) as measured by B cell ELISpot in PBMC from mRNA-LNP or Protein+3M-052-SE vaccinees, while (G–H) contain mRNA-LNP and Protein+3M-052-SE ASC responses, respectively, in LN at W6. Different symbols represent individual animals ( Table S1 ). Solid lines represent median values.

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: Characterization of Spike-specific B cell responses two weeks post boost. CD20 + CD27 + memory B cells that co-stained with fluorochrome-conjugated SARS-CoV-2 spike protein in mRNA-LNP (red) or Protein+3M-052-SE (blue) vaccinees in blood ( A - B ) or LN ( C - D ). Frequencies are expressed as percent of total memory B cells. The gating strategy is provided in Supplementary Figure S8. ( E–F) portray antibody secreting cell (ASC) as measured by B cell ELISpot in PBMC from mRNA-LNP or Protein+3M-052-SE vaccinees, while (G–H) contain mRNA-LNP and Protein+3M-052-SE ASC responses, respectively, in LN at W6. Different symbols represent individual animals ( Table S1 ). Solid lines represent median values.

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques: Staining, Enzyme-linked Immunospot

    Spike-specific CD4 + T cell responses in SARS-CoV-2 immunized infant macaques. Intracellular cytokine staining for IL-2, IL-17, IFN-γ, and TNF-α was performed on PBMC at weeks 0, 6, 4, 8, and 14 to assess T-cell responses to a peptide pool encompassing the entire SARS-CoV-2 spike protein. (A–D) display responses detected in Protein+3M-052+SE vaccinees (blue). (E-H) portray cytokine responses from mRNA-LNP recipients (red). The dashed lines represent week 0 values plus 2 standard deviations and define the cutoff for positive cytokine responses. Different symbols represent individual animals ( Table S1 ).

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: Spike-specific CD4 + T cell responses in SARS-CoV-2 immunized infant macaques. Intracellular cytokine staining for IL-2, IL-17, IFN-γ, and TNF-α was performed on PBMC at weeks 0, 6, 4, 8, and 14 to assess T-cell responses to a peptide pool encompassing the entire SARS-CoV-2 spike protein. (A–D) display responses detected in Protein+3M-052+SE vaccinees (blue). (E-H) portray cytokine responses from mRNA-LNP recipients (red). The dashed lines represent week 0 values plus 2 standard deviations and define the cutoff for positive cytokine responses. Different symbols represent individual animals ( Table S1 ).

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques: Staining

    S-specific B cell gating strategy. Panel A shows a representative plot from RM7; Panel B shows a naive, age-matched control macaque without SARS-CoV-2 S protein conjugates; Panel C shows the same donor macaque with the SARS-CoV-2 S protein conjugates included.

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: S-specific B cell gating strategy. Panel A shows a representative plot from RM7; Panel B shows a naive, age-matched control macaque without SARS-CoV-2 S protein conjugates; Panel C shows the same donor macaque with the SARS-CoV-2 S protein conjugates included.

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques:

    Th1 and Th2 cytokines in plasma of infant rhesus macaques prior to and following SARS-CoV-2 vaccination. Plasma levels of IFN-γ ( panel A ) IL-2 ( panel B ), IL-4 ( panel C ) and IL-13 ( panel D ) were measured by multiplex Luminex assay. Different symbols represent individual animals in the mRNA-LNP (red) or Protein+3M-052-SE (blue) vaccine groups, respectively ( Table S1 ). Horizontal lines represent median values.

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: Th1 and Th2 cytokines in plasma of infant rhesus macaques prior to and following SARS-CoV-2 vaccination. Plasma levels of IFN-γ ( panel A ) IL-2 ( panel B ), IL-4 ( panel C ) and IL-13 ( panel D ) were measured by multiplex Luminex assay. Different symbols represent individual animals in the mRNA-LNP (red) or Protein+3M-052-SE (blue) vaccine groups, respectively ( Table S1 ). Horizontal lines represent median values.

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques: Multiplex Assay, Luminex

    SARS-CoV-2 vaccine-elicited binding antibody responses in infant rhesus macaques. Plasma and saliva were collected before vaccination (W0), at W4 -just prior to the boost-, two weeks post boost (W6), at W8, W14, W18 and W22 from infant RM vaccinated with 30 µg mRNA encoding S-2P spike protein in lipid nanoparticles (n=8; red) or with 15 µg prefusion SARS-CoV-2 S-2P spike protein formulated with 3M-052 adjuvant (n=8; blue). (A): S-2P protein-specific antibody responses were measured by enzyme-linked immunosorbent assay (ELISA). Serial dilutions of plasma starting at 1:40 were assayed for IgG binding to SARS-CoV-2 spike. Data are reported as log 10 area under the curve (AUC) values. (B): Salivary RBD-specific IgG was measured by binding antigen multiplex assay (BAMA) using serial dilutions of saliva. (C): Antibody epitope specificity measured by BAMA. Plasma was diluted 1:10,000 to measure binding to different domains of the spike protein, including the full-length S protein, S1, RBD, NTD, and S2. Binding antibody responses are reported as log 10 transformed mean fluorescence intensity (MFI) after subtraction of background values. Red or blue lines and symbols represent the mRNA or protein vaccine groups, respectively, with different symbols representing individual animals ( Table S1 ).

    Journal: bioRxiv

    Article Title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

    doi: 10.1101/2021.04.05.438479

    Figure Lengend Snippet: SARS-CoV-2 vaccine-elicited binding antibody responses in infant rhesus macaques. Plasma and saliva were collected before vaccination (W0), at W4 -just prior to the boost-, two weeks post boost (W6), at W8, W14, W18 and W22 from infant RM vaccinated with 30 µg mRNA encoding S-2P spike protein in lipid nanoparticles (n=8; red) or with 15 µg prefusion SARS-CoV-2 S-2P spike protein formulated with 3M-052 adjuvant (n=8; blue). (A): S-2P protein-specific antibody responses were measured by enzyme-linked immunosorbent assay (ELISA). Serial dilutions of plasma starting at 1:40 were assayed for IgG binding to SARS-CoV-2 spike. Data are reported as log 10 area under the curve (AUC) values. (B): Salivary RBD-specific IgG was measured by binding antigen multiplex assay (BAMA) using serial dilutions of saliva. (C): Antibody epitope specificity measured by BAMA. Plasma was diluted 1:10,000 to measure binding to different domains of the spike protein, including the full-length S protein, S1, RBD, NTD, and S2. Binding antibody responses are reported as log 10 transformed mean fluorescence intensity (MFI) after subtraction of background values. Red or blue lines and symbols represent the mRNA or protein vaccine groups, respectively, with different symbols representing individual animals ( Table S1 ).

    Article Snippet: Mapping plasma S-specific IgGSARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) and NTD (Sinobiological cat# 40591-V49H) were conjugated to Magplex beads (Bio-Rad, Hercules, CA).

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Multiplex Assay, Transformation Assay, Fluorescence

    Comparison of seroconversion in patients with COVID-19 and healthy individuals. ( A ) ELISA with S-RBD protein coating and 1:100 dilution of repeated serum samples of patients with SARS-CoV-2 and healthy individuals. Absorbance normalized to the respective no antigen control for each sample at 450 nm reported. SARS-CoV-2 (blue), n = 88 (from 21 patients); HS 2017–2019 (white), n = 104; HS 2020 (white), n = 308. Arrows list consecutive serum samples evaluated for each case. Inset graphs depict the data separated based on healthy serum collected from 2017 to 2019 (left inset) and 2020 (right inset). ( B ) ELISA with N-protein coating and 1:100 dilution of the first and last serum samples of patients with SARS-CoV-2 and healthy individuals. Absorbance normalized to the respective no antigen control for each sample at 450 nm reported. SARS-CoV-2 (blue), n = 37 (from 21 patients); HS 2017–2019 (white), n = 103; HS 2020 (white), n = 308. Arrows list consecutive serum samples evaluated for each case. Inset graphs depict the data separated based on healthy serum collected from 2017 to 2019 (top inset) and 2020 (bottom inset). ( C ) Pie charts depicting percentage of samples positive for indicated antigens. SARS-CoV-2, n = 21; HS 2017–2019, n = 103; HS 2020, n = 308; non–COVID-19 samples (NCSs), n = 45; HIV, n = 7; all, n = 484.

    Journal: JCI Insight

    Article Title: Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity

    doi: 10.1172/jci.insight.142386

    Figure Lengend Snippet: Comparison of seroconversion in patients with COVID-19 and healthy individuals. ( A ) ELISA with S-RBD protein coating and 1:100 dilution of repeated serum samples of patients with SARS-CoV-2 and healthy individuals. Absorbance normalized to the respective no antigen control for each sample at 450 nm reported. SARS-CoV-2 (blue), n = 88 (from 21 patients); HS 2017–2019 (white), n = 104; HS 2020 (white), n = 308. Arrows list consecutive serum samples evaluated for each case. Inset graphs depict the data separated based on healthy serum collected from 2017 to 2019 (left inset) and 2020 (right inset). ( B ) ELISA with N-protein coating and 1:100 dilution of the first and last serum samples of patients with SARS-CoV-2 and healthy individuals. Absorbance normalized to the respective no antigen control for each sample at 450 nm reported. SARS-CoV-2 (blue), n = 37 (from 21 patients); HS 2017–2019 (white), n = 103; HS 2020 (white), n = 308. Arrows list consecutive serum samples evaluated for each case. Inset graphs depict the data separated based on healthy serum collected from 2017 to 2019 (top inset) and 2020 (bottom inset). ( C ) Pie charts depicting percentage of samples positive for indicated antigens. SARS-CoV-2, n = 21; HS 2017–2019, n = 103; HS 2020, n = 308; non–COVID-19 samples (NCSs), n = 45; HIV, n = 7; all, n = 484.

    Article Snippet: The stock S-RBD (2.5 μg/mL; 93.28 nM) was used to coat ELISA plates (Sino Biological 40592-V08H).

    Techniques: Enzyme-linked Immunosorbent Assay

    Detection of serum binding antibodies against SARS-CoV-2 proteins in patients with PCR-confirmed COVID-19 and healthy samples. ( A ) Timeline of COVID-19 diagnosis/ICU admittance, serum sample collection, and convalescent plasma (CP) administration. Time 0 is defined as day of COVID-19 diagnosis (PCR positive for SARS-CoV-2) and ICU admittance. Blood collections are denoted in gray and CP administration is denoted in pink. Patients were stratified based on current status (recovered, hospitalized, or deceased). Patient 29 from our cohort had symptoms but was PCR negative for SARS-CoV-2; this sample was not included in figures since there was no proof of disease. ( B ) Schematic of SARS-CoV-2 viral structure (top panel) and antigens assayed (bottom panel). S-protein, light orange; envelope protein, yellow; membrane glycoprotein, dark orange; RNA, blue; N-protein, green. Absorbance normalized to the respective no antigen control for each sample at 450 nm plotted for S-RBD (left panel), and N-protein (right panel), antigen coating with the most recent (or only) SARS-CoV-2 samples not treated with CP ( n = 21) and healthy samples collected in 2017–2019 (HS 2017–2019, n = 104 for S-RBD, n = 103 for N-protein) and 2020 (HS 2020, n = 308). Data are presented with each dot representing the mean normalized absorbance for a given serum sample; the red bar depicts the median ± interquartile range of all samples. HS, healthy sample; NC (line), negative control cutoff (see Methods). Kruskal-Wallis with Dunn’s multiple-comparisons test performed. **** P

    Journal: JCI Insight

    Article Title: Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity

    doi: 10.1172/jci.insight.142386

    Figure Lengend Snippet: Detection of serum binding antibodies against SARS-CoV-2 proteins in patients with PCR-confirmed COVID-19 and healthy samples. ( A ) Timeline of COVID-19 diagnosis/ICU admittance, serum sample collection, and convalescent plasma (CP) administration. Time 0 is defined as day of COVID-19 diagnosis (PCR positive for SARS-CoV-2) and ICU admittance. Blood collections are denoted in gray and CP administration is denoted in pink. Patients were stratified based on current status (recovered, hospitalized, or deceased). Patient 29 from our cohort had symptoms but was PCR negative for SARS-CoV-2; this sample was not included in figures since there was no proof of disease. ( B ) Schematic of SARS-CoV-2 viral structure (top panel) and antigens assayed (bottom panel). S-protein, light orange; envelope protein, yellow; membrane glycoprotein, dark orange; RNA, blue; N-protein, green. Absorbance normalized to the respective no antigen control for each sample at 450 nm plotted for S-RBD (left panel), and N-protein (right panel), antigen coating with the most recent (or only) SARS-CoV-2 samples not treated with CP ( n = 21) and healthy samples collected in 2017–2019 (HS 2017–2019, n = 104 for S-RBD, n = 103 for N-protein) and 2020 (HS 2020, n = 308). Data are presented with each dot representing the mean normalized absorbance for a given serum sample; the red bar depicts the median ± interquartile range of all samples. HS, healthy sample; NC (line), negative control cutoff (see Methods). Kruskal-Wallis with Dunn’s multiple-comparisons test performed. **** P

    Article Snippet: The stock S-RBD (2.5 μg/mL; 93.28 nM) was used to coat ELISA plates (Sino Biological 40592-V08H).

    Techniques: Binding Assay, Polymerase Chain Reaction, Negative Control

    Graphical illustrations of the COVID-19 related immunoassays that were performed with our microfluidic chemiluminescent ELISA platform, including (A) affinity evaluation of calibration antibodies, (B) detection of circulating anti-SARS-CoV-2 S1 IgG in serum samples, and (C) detection of SARS-CoV-2 antigens such as S1 and N protein.

    Journal: Biosensors & Bioelectronics

    Article Title: Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation

    doi: 10.1016/j.bios.2020.112572

    Figure Lengend Snippet: Graphical illustrations of the COVID-19 related immunoassays that were performed with our microfluidic chemiluminescent ELISA platform, including (A) affinity evaluation of calibration antibodies, (B) detection of circulating anti-SARS-CoV-2 S1 IgG in serum samples, and (C) detection of SARS-CoV-2 antigens such as S1 and N protein.

    Article Snippet: Human-cell-expressed SARS-CoV-2 Spike S1-His recombinant protein (40591-V08H), human-cell-expressed SARS-CoV-2 Spike RBD-His recombinant protein (40592-V08H) and insect-cell-expressed SARS-CoV Spike S1-His recombinant protein (40150-V08B1) were provided by Sino Biological.

    Techniques: Chemiluminescent ELISA